FDA pharmacologic class
HER2/neu Receptor Antagonist
7 medicines are in FDA's class of her2/neu receptor antagonists: trastuzumab (Herceptin), trastuzumab-strf (Hercessi), margetuximab (Margenza), pertuzumab (Perjeta), trastuzumab-dkst (Ogivri), trastuzumab-qyyp (Trazimera) and ontruzant; 2 combination products also contain one. 0 of the 9 are listed from generic labelers (FDA NDC Directory, October 8, 2026).
Which medicines are her2/neu receptor antagonist?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Trastuzumab | Ogivri, Kanjinti, Herzuma | none listed | n/a | Yes | No current entry | 0 |
| Trastuzumab-strf | Hercessi | none listed | n/a | Yes | No current entry | 0 |
| Hyaluronidase and pertuzumab and trastuzumab | Phesgo | none listed | n/a | Yes | No current entry | 0 |
| Margetuximab | Margenza | none listed | n/a | Yes | No current entry | 0 |
| Hyaluronidase and trastuzumab | Herceptin | none listed | n/a | Yes | No current entry | 0 |
| Pertuzumab | Perjeta | none listed | n/a | Yes | No current entry | 1 |
| Trastuzumab-dkst | Ogivri | none listed | n/a | No | No current entry | 0 |
| Trastuzumab-qyyp | Trazimera | none listed | n/a | No | No current entry | 0 |
| Ontruzant | none listed | none listed | n/a | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)